Amgen Inc.
Long

🔎💊 Amgen Innovations & Strategic Moves 🚀

152
🌟 Lumakras Breakthrough:
Amgen (AMGN) pioneers cancer treatment with Lumakras, the first medication targeting a mutation found in approximately 13% of lung cancer patients.

💰 Strategic Acquisition:
Amgen acquires Horizon Therapeutics for a substantial $28 billion in cash.
Incorporates Tepezza, an FDA-approved medicine for thyroid eye disease, into Amgen's product portfolio.

📈 Market Outlook:
Bullish stance on AMGN suggests support levels above $260.00-$265.00.
Anticipated upside target in the range of $360.00-$365.00.

Exciting developments in biotech and strategic expansion for Amgen! 🌐💉

#AmgenInnovation #Biotech #StockMarket 📰📊

āļ„āļģāļˆāļģāļāļąāļ”āļŠāļīāļ—āļ˜āļīāđŒāļ„āļ§āļēāļĄāļĢāļąāļšāļœāļīāļ”āļŠāļ­āļš

āļ‚āđ‰āļ­āļĄāļđāļĨāđāļĨāļ°āļšāļ—āļ„āļ§āļēāļĄāđ„āļĄāđˆāđ„āļ”āđ‰āļĄāļĩāļ§āļąāļ•āļ–āļļāļ›āļĢāļ°āļŠāļ‡āļ„āđŒāđ€āļžāļ·āđˆāļ­āļāđˆāļ­āđƒāļŦāđ‰āđ€āļāļīāļ”āļāļīāļˆāļāļĢāļĢāļĄāļ—āļēāļ‡āļāļēāļĢāđ€āļ‡āļīāļ™, āļāļēāļĢāļĨāļ‡āļ—āļļāļ™, āļāļēāļĢāļ‹āļ·āđ‰āļ­āļ‚āļēāļĒ, āļ‚āđ‰āļ­āđ€āļŠāļ™āļ­āđāļ™āļ° āļŦāļĢāļ·āļ­āļ„āļģāđāļ™āļ°āļ™āļģāļ›āļĢāļ°āđ€āļ āļ—āļ­āļ·āđˆāļ™ āđ† āļ—āļĩāđˆāđƒāļŦāđ‰āļŦāļĢāļ·āļ­āļĢāļąāļšāļĢāļ­āļ‡āđ‚āļ”āļĒ TradingView āļ­āđˆāļēāļ™āđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄāđƒāļ™ āļ‚āđ‰āļ­āļāļģāļŦāļ™āļ”āļāļēāļĢāđƒāļŠāđ‰āļ‡āļēāļ™